SCIENTURE Q1 revenue $56k (+449% YoY); gross margin 95.6%; net loss $3.4M; secures $11M debt

Scienture Holdings, Inc.

2026-Q1 EPS reported -$0.08 vs consensus -$0.22 ▲ beat (+64.3%)

Revenue $56k (+449% YoY); gross profit $54k (+7,900%); gross margin 95.6% vs 6.6%.
Net loss $3.4M vs $3.1M; operating expenses flat at ~$3.56M.
USPTO granted third patent for Arbli (losartan) extending exclusivity through 2041; REZENOPY got Orange Book patent.
GPO agreements for REZENOPY covering 5,000+ institutions; sales force starts June 1, 2026.
Secured $11M non-dilutive debt financing to support commercialization and R&D pipeline.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001493152-26-025062
form_type: 8-K
ticker: SCNX
cik: 0001382574
company_name: Scienture Holdings, Inc.
filed_at: 2026-05-22T21:00:37+00:00
discovered_at: 2026-05-22T21:02:00.241160+00:00
generated_at: 2026-05-22T21:05:09.660714+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: positive
materiality_score: 0.6
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001493152-26-025062
json_url: https://secwatch.observer/filing/0001493152-26-025062.json
markdown_url: https://secwatch.observer/filing/0001493152-26-025062.md
text_url: https://secwatch.observer/filing/0001493152-26-025062.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/0001493152-26-025062-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1382574/000149315226025062/form8-k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001493152-26-025062

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.